Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs By: Investor Brand Network February 11, 2022 at 09:50 AM EST Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”)The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation”ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has made a case for increasing the rapidity and effectiveness of medication absorption through Lexaria’s patented DehydraTECH(TM) technology. Recent clinical studies have shown the potential for improved bio-effectiveness of nicotine and cannabidiol (“CBD”) when processed with DehydraTECH for the potential treatment of conditions such as high blood pressure and arterial stiffness, for example. In a Feb. 2 news release, the company announced it has also observed successes when administering… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW)Denver, Coloradocbdwire.com303.498.7722 OfficeEditor@CBDWire.com CBDWire is part of the InvestorBrandNetwork. Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs By: Investor Brand Network February 11, 2022 at 09:50 AM EST Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”)The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation”ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has made a case for increasing the rapidity and effectiveness of medication absorption through Lexaria’s patented DehydraTECH(TM) technology. Recent clinical studies have shown the potential for improved bio-effectiveness of nicotine and cannabidiol (“CBD”) when processed with DehydraTECH for the potential treatment of conditions such as high blood pressure and arterial stiffness, for example. In a Feb. 2 news release, the company announced it has also observed successes when administering… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW)Denver, Coloradocbdwire.com303.498.7722 OfficeEditor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.
Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”)The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation”ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has made a case for increasing the rapidity and effectiveness of medication absorption through Lexaria’s patented DehydraTECH(TM) technology. Recent clinical studies have shown the potential for improved bio-effectiveness of nicotine and cannabidiol (“CBD”) when processed with DehydraTECH for the potential treatment of conditions such as high blood pressure and arterial stiffness, for example. In a Feb. 2 news release, the company announced it has also observed successes when administering… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW)Denver, Coloradocbdwire.com303.498.7722 OfficeEditor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.
